shattucklabs.com (STTK): Aggregate Business Value
The price trajectory of Shattuck Labs, Inc. (STTK) reflects the enterprise value, which currently stands at 373.46. The business remains vulnerable due to a lack of revenue and massive expenditures on new drug trials; however, the company is valued for its ARC platform, which creates unique anti-cancer proteins. The environmental footprint is minimal, as operations are limited to secure laboratories and a transition to electronic document management.
Shattuck Labs (STTK) - metric breakdowns and financial figures
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Comprehensive company analysis:Shattuck Labs, Inc. (STTK)
Enterprise Value represents the total acquisition cost of a business. The Enterprise Value trend on this chart reflects market capitalization adjusted for net debt. This metric demonstrates the actual cost to a buyer, accounting for debt load and liquid reserves. For Shattuck Labs, Inc. (STTK), this indicator confirms the biotech's investment attractiveness. Institutional capital's confidence in Taylor Schreiber's team stabilizes the company's valuation.
Competitor analysis for Shattuck Labs, Inc.
ARGX - Aggregate Business Value|Real Price to Acquire Entire Company BioNTech Group BNTX|ABVX: Aggregate Business Value|ADMA: Total Company Value|PTGX (protagonist-inc.com) - Enterprise Value|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value BioCryst Pharmaceuticals (BCRX)|VERA: Value Adjusted for Debt and Cash|DNTH (Dianthus Pharma) - Total Company Value|Pharvaris Pharma (PHVS) - Real Price to Acquire Entire Company|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com (TRML)|Precigen (PGEN) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Pharming Group NV (PHAR)|Enterprise Value NKTR|Upstream Pharma - Company Buyout Price|ZBIO: Total Company Value|IMNM: Real Price to Acquire Entire Company|GOSS (Gossamer Bio) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|SEPN (Septerna Corp) - Real Price to Acquire Entire Company|Enterprise Value PVLA|Total Company Value Savara Inc. SVRA|Business Value rigel.com (RIGL)|ANAB: Enterprise Value|Astria Therapeutics Inc - Total Enterprise Value|Total Company Value ENGN (enGene Bio)|RAPT - Company Buyout Price|Enterprise Value aerovatetx.com JBIO|aclaristx.com (ACRS) - Value Adjusted for Debt and Cash|KYTX (Kyverna Therapeutics, Inc.) - Enterprise Value|Enterprise Value Tiziana Life Sciences Ltd. (TLSA)|Real Price to Acquire Entire Company Cabaletta Bio, Inc|Aggregate Business Value Ventyx Biosciences, Inc VTYX|Real Price to Acquire Entire Company Theratechnologies Inc. (THTX)|AVTX - Aggregate Business Value|Eledon Pharmaceuticals, Inc. - Real Price to Acquire Entire Company|AGEN - Enterprise Value|CLYM (Climb Bio, Inc.) - Enterprise Value|ZURA (Zura Bio Ltd) - Real Price to Acquire Entire Company|ATYR (aTyr Pharma, Inc.) - Total Company Value|Enterprise Value Adagene Corp (ADAG)|ImageneBio Inc (IMA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash EQ (equilliumbio.com)|Total Company Value Connect Biopharma Holdings Limited CNTB|Total Company Value Immunic Therapeutics IMUX|Atara Biotherapeutics Inc - Enterprise Value|IFRX - Enterprise Value|X4 Pharmaceuticals, Inc. (XFOR) - Enterprise Value|ACET (Adicet Bio, Inc.) - Total Company Value|CELU: Total Company Value|Company Buyout Price INmune Bio Corporation (INMB)|Barinthus Biotherapeutics (BRNS) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash kezarlifesciences.com (KZR)|Enterprise Value SABS|Akari Therapeutics PLC - Company Buyout Price|Enlivex Therapeutics, Ltd. (ENLV) - Total Company Value|QTTB - Business Value|GOVX (GeoVax Labs, Inc.) - Enterprise Value|Real Price to Acquire Entire Company edesabiotech.com|IBIO: Real Price to Acquire Entire Company|Company Buyout Price CARM|XTLB (XTL Biopharmaceuticals, Ltd.) - Total Company Value|Company Buyout Price boltbio.com BOLT|Real Price to Acquire Entire Company HCW Biologics (HCWB)|APVO - Aggregate Business Value|Real Price to Acquire Entire Company AIM ImmunoTech Inc. AIM|ADTX: Aggregate Business Value|GRI: Total Company Value|XRTX (XORTX Corp) - Enterprise Value|Total Company Value Vyome Holdings Inc HIND|Full Business Value revbiosciences.com|Indaptus Therapeutics, Inc. (INDP) - Enterprise Value|Value Adjusted for Debt and Cash Scinai Immunotherapeutics Ltd (SCNI)|Enterprise Value CALI (CalciMedica)|Affimed NV - Enterprise Value|Total Company Value Allakos Therapeutics (ALLK)|HOOK: Value Adjusted for Debt and Cash|IGMS (igmbio.com) - Total Company Value|iTeos Therapeutics Inc (ITOS) - Real Price to Acquire Entire Company|OCEA (Ocean Bio) - Enterprise Value|Enterprise Value TC BioPharm Ltd (TCBP)|Third Harmonic Bio (THRD) - Real Price to Acquire Entire Company